Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801


Por: Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM and Márquez-Rodas, I

Publicada: 1 jun 2026 Ahead of Print: 1 dic 2025
Resumen:
BackgroundThe clinical presentation of melanoma of unknown primary (MUP) and its treatment patterns remain incompletely characterized.MethodsGEM1801 is a prospective, observational study in Spain enrolling patients with advanced melanoma. This analysis describes the clinical features and outcomes of patients with MUP.ResultsFrom August 2018 to December 2022, 893 evaluable patients were enrolled, of whom 133 (14.9%) had MUP. Median age was 63 years (range 24-93); 81 (60.9%) were men; 117 (88.0%) had distant metastases; lactate dehydrogenase (LDH) was elevated in 50 (37.6%); and 79 (54.9%) had BRAF-mutated tumors. Compared with patients with a known primary, immunotherapy was prescribed less frequently (adjuvant: 15.5% vs 27.2%, p = 0.007; first-line metastatic: 53.6% vs 64.0%, p = 0.039). Median progression-free survival (PFS) was 18.9 months (95% CI: 4.4-NR), 13.3 months (95% CI: 7.1-27.5), and 6.7 months (95% CI: 3.5-NR), and median overall survival (OS) was 24.9 months (95% CI: 24.1-NR), 13.9 months (95% CI: 8.3-NR), and 17.9 months (95% CI: 9.6-NR) in patients with BRAF-mutated tumors treated with immunotherapy, BRAF-mutated tumors treated with targeted therapy, and BRAF-wild-type tumors treated with immunotherapy, respectively.ConclusionsIn Spain, MUP is characterized by multi-organ involvement and frequent brain metastases and was associated with worse outcomes than the overall melanoma cohort. A diagnosis of MUP appears to influence treatment allocation, particularly regarding immunotherapy. When stratified by BRAF status and treatment type, no survival differences were observed between MUP and melanoma of known primary, except for OS among patients with MUP and BRAF-mutated tumors treated with immunotherapy.Clinical trial identificationclinicaltrials.gov: NCT03605771.

Filiaciones:
Cerezuela-Fuentes, P:
 Hosp Clin Univ Virgen de La Arrixaca, Med Oncol Dept, Inst Murciano Invest Sanitaria IMIB, Ciudad De Murcia, Spain

Piñero-Madrona, A:
 Univ Virgen de La Arrixaca, Hosp Clin, Dept Surg, IMIB Arrixaca, Ciudad De Murcia, Spain

Muñoz-Couselo, E:
 Hosp Univ Vall dHebron, Med Oncol Dept, Barcelona, Spain

 Vall dHebron Inst Oncol VHIO, Barcelona, Spain

:
 Hosp Germans Trias I Pujol, Inst Catalan Oncol, Med Oncol Dept, ICO Badalona, Badalona, Spain

Berciano-Guerrero, MA:
 Hosp Univ Reg & Virgen de La Victoria HURyVV, Unidad Interctr Oncol, Inst Invest Biomed Malaga IBIMA, Malaga, Spain

Majem, M:
 Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain

Espinosa, E:
 La Paz Univ Hosp, Med Oncol Dept, CIBERONC, Madrid, Spain

Soria, A:
 Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain

Castaño, AG:
 Hosp Univ Marques de Valdecilla, Med Oncol Dept, Santander, Spain

Crespo, G:
 Hosp Univ Burgos, Med Oncol Dept, Burgos, Spain

Sanz, LG:
 Hosp Univ Puerta de Hierro, Med Oncol Dept, Madrid, Spain

de la Rosa, CA:
 Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain

Fernández-Morales, LA:
 Hosp Univ Parc Tauli, Med Oncol Dept, Sabadell, Spain

Puértolas, T:
 Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain

Rodríguez, JF:
 Hosp Univ Rio Hortega, Med Oncol Dept, Valladolid, Spain

de la Borbolla, MR:
 Univ Hosp Valme, Med Oncol Dept, Seville, Spain

Bellido, L:
 Complejo Asistencial Univ Salamanca, Med Oncol Dept, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

Castro, RL:
 Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain

Pérez, VN:
 Hosp Costa del Sol, Med Oncol Dept, Marbella, Spain

Arroyo, FRG:
 Complejo Hosp Univ Pontevedra, Med Oncol Dept, Pontevedra, Spain

Guzmán, JCV:
 Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain

Balea, BC:
 Hosp Univ Lucus Augusti, Serv Med Intens, Lugo, Spain

Hernández, B:
 Hosp Univ La Princesa, Med Oncol Dept, Madrid, Spain

Algarra, SM:
 Clin Univ Navarra, Med Oncol Dept, Pamplona, Spain

Márquez-Rodas, I:
 Univ Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain

Hosp Univ San Pedro de Alcantara, Med Oncol Dept, Caceres, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
Springer-Verlag Italia, GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 28 Número: 6
Páginas: 2377-2385
WOS Id: 001642862200001
ID de PubMed: 41420791

MÉTRICAS